Market Place
Sourcing Support
Laekna with Lilly to develop muscle preserving obesity drug
21 Nov 2024 //
PRESS RELEASE
Laekna Lae002 Lae001 Approval: Fda Phase 3 Prostate Cancer Trial
23 May 2024 //
PR NEWSWIRE
Laekna Announces Poster Presentations on Discovered Drug Candidates at AACR 2024
07 Apr 2024 //
PR NEWSWIRE
Laekna Announces Poster Presentation on Internally-Discovered Antibody for NASH
03 Jan 2024 //
PR NEWSWIRE
2023 SABCS | Laekna Reports Afuresertib Phase Ib Breast Cancer Study Results
11 Dec 2023 //
PR NEWSWIRE
Laekna bags $100M in Hong Kong IPO while Merck-partnered Kelun seeks up to $208M
29 Jun 2023 //
ENDPTS
Laekna doses first subject in Phase I/II prostate cancer trial
06 Sep 2022 //
CLINICALTRIALSARENA
Innovent and Laekna begin Dosing with Three-drug Combination in PI/II Study
31 Jul 2022 //
PRNEWSWIRE
Laekna doses first subjects in Phase Ib/III breast cancer therapy trial
27 May 2022 //
CLINICALTRIALSARENA
Laekna Therapeutics Begins Dosing in PIb/III Study of Afuresertib + Fulvestrant
26 May 2022 //
PRNEWSWIRE
Small Molecules Attract Investors As Two Chinese Biotechs Bag $161m
19 May 2022 //
SCRIP
Laekna Tx Appoints Jeff Porter, Ph.D. as Chairman of Scientific Advisory Board
29 Mar 2022 //
PRNEWSWIRE
Laekna, Innovent obtain IND approval for combination therapy in solid tumors
09 Jan 2022 //
PRNEWSWIRE
Laekna Therapeutics bags NMPA nod for PIb/III study of afuresertib+fulvestrant
28 Aug 2021 //
PHARMABIZ
Laekna Therapeutics Receives IND Approvals in China and US
26 Aug 2021 //
PRNEWSWIRE
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.